Table 1.

Patients' characteristics and extension of disease

HIV-seronegative patientsHIV-positive patients
No. patients1631
Age (y)
    Median5834
    Range29-7026-56
Gender, n (%) males9 (56)22 (71)
Eastern Cooperative Oncology Group-performance status,* n (%)
    0-16 (38)0 (0)
    2-39 (56)8 (26)
    41 (6)2 (6)
    50 (0)21 (68)
Prior cancer, n (%)1 (6)1 (3)
Histotype, n (%)
    Diffuse large B-cell12 (75)29 (94)
    Burkitt like2 (13)0 (0)
    Lymphoblastic1 (6)0 (0)
    Anaplastic large T-cell Ki11 (6)0 (0)
    Unclassified0 (0)2 (6)
Systemic symptoms, n (%)1 (6)14 (45)
Lactate dehydrogenase ratio >1, n (%)3/11 (27)20/25 (80)
Ocular disease, n (%)2/14 (14)0/13 (0)
Positive cerebrospinal fluid cytology examination, n (%)2/14 (14)1/14 (7)
High cerebrospinal fluid protein level,,§ n (%)5/8 (63)11/13 (85)
Multiple lesions, n (%)8 (50)12/25 (48)
Involvement of deep structures, n (%)8 (50)23 (74)
  • * Performance status according to the Eastern Cooperative Oncology Group score at the time of histopathologic diagnosis.

  • Histotype was defined according to the REAL/WHO classification. All cases but one shared a B-cell phenotype.

  • Relationship between the number of positive cases and the total number of assessed patients.

  • § The cutoff for normal cerebrospinal fluid protein concentration was 45 mg/dL in patients ages ≤60 years and 60 mg/dL in patients ages >60 years.

  • Involvement of deep structures of the brain that is basal ganglia and/or corpus callosum and/or brain stem and/or cerebellum.